TW200728299A - New pyrazine derivatives - Google Patents

New pyrazine derivatives

Info

Publication number: TW200728299A
Authority: TW; Taiwan
Prior art keywords: antagonist; diseases; pyrazine derivatives; kinase inhibitor; receptor
Prior art date: 2005-07-29

Application number

TW095127615A

Other languages

English (en)

Inventor

Juan Bernat Vidal

Trias Cristina Esteve

Pueyo Lidia Soca

Paul Robert Eastwood

Original Assignee

Almirall Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-29

Filing date

2006-07-28

Publication date

2007-08-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35945119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200728299(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-07-28 Application filed by Almirall Lab filed Critical Almirall Lab

2007-08-01 Publication of TW200728299A publication Critical patent/TW200728299A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW095127615A 2005-07-29 2006-07-28 New pyrazine derivatives TW200728299A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200501876A ES2270715B1 (es)	2005-07-29	2005-07-29	Nuevos derivados de pirazina.

Publications (1)

Publication Number	Publication Date
TW200728299A true TW200728299A (en)	2007-08-01

Family

ID=35945119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095127615A TW200728299A (en)	2005-07-29	2006-07-28	New pyrazine derivatives

Country Status (22)

Country	Link
US (2)	US7790728B2 (zh)
EP (1)	EP1922313A1 (zh)
JP (1)	JP2009502837A (zh)
KR (1)	KR20080040681A (zh)
CN (1)	CN101268064A (zh)
AR (1)	AR056008A1 (zh)
AU (1)	AU2006278875A1 (zh)
CA (1)	CA2616428A1 (zh)
EC (1)	ECSP088113A (zh)
ES (1)	ES2270715B1 (zh)
IL (1)	IL188725A0 (zh)
MX (1)	MX2008001035A (zh)
NO (1)	NO20080451L (zh)
NZ (1)	NZ565150A (zh)
PE (1)	PE20070407A1 (zh)
RU (1)	RU2417994C2 (zh)
SG (1)	SG162805A1 (zh)
TW (1)	TW200728299A (zh)
UA (1)	UA93883C2 (zh)
UY (1)	UY29672A1 (zh)
WO (1)	WO2007017096A1 (zh)
ZA (1)	ZA200800353B (zh)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8518950B2 (en) *	2005-01-25	2013-08-27	Synta Pharmaceuticals Corp.	2-amido pyrazines for inflammation and immune related uses
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
CN101573360A (zh)	2006-10-19	2009-11-04	西格诺药品有限公司	杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
ES2303776B1 (es) *	2006-12-29	2009-08-07	Laboratorios Almirall S.A.	Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es)	2007-03-02	2010-03-16	Laboratorios Almirall S.A.	Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CN101945877B (zh) *	2008-02-25	2013-07-03	霍夫曼-拉罗奇有限公司	吡咯并吡嗪激酶抑制剂
WO2009118759A2 (en)	2008-03-26	2009-10-01	Advinus Therapeutics Pvt. Ltd.,	Heterocyclic compounds as adenosine receptor antagonist
EP2108641A1 (en)	2008-04-11	2009-10-14	Laboratorios Almirall, S.A.	New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en)	2008-04-28	2009-11-04	Laboratorios Almirall, S.A.	New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
SI2394999T1 (sl)	2009-02-06	2014-05-30	Nippon Shinyaku Co., Ltd.	Derivati aminopirazina in zdravilo
CA2755117C (en)	2009-03-13	2018-09-11	Advinus Therapeutics Private Limited	Substituted fused pyrimidine compounds
EP2499142B1 (en)	2009-11-09	2016-09-21	Advinus Therapeutics Limited	Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2322176A1 (en)	2009-11-11	2011-05-18	Almirall, S.A.	New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
EP2338890A1 (en)	2009-12-22	2011-06-29	Bayer CropScience AG	4,7-Diazaindole derivatives and their use as fungicides
MX352415B (es) *	2010-02-05	2017-11-22	Heptares Therapeutics Ltd Star	Derivados de 1, 2, 4-triazin-4-amina.
CN101817823B (zh) *	2010-03-31	2012-09-12	上海毕得医药科技有限公司	4，7-二氮杂吲哚及其5位取代物的制备方法
PE20130404A1 (es)	2010-07-14	2013-04-17	Novartis Ag	Compuestos heterociclicos agonistas del receptor ip
JP5827998B2 (ja)	2010-09-13	2015-12-02	アドヴィナス・セラピューティックス・リミテッド	Ａ２ｂアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
TWI659030B (zh) *	2011-10-26	2019-05-11	諾華公司	Ｉｐ受體促效劑雜環化合物
ES2561353T3 (es) *	2012-01-13	2016-02-25	Novartis Ag	Sales de un agonista del receptor IP
US20150005311A1 (en) *	2012-01-13	2015-01-01	Novartis Ag	IP receptor agonist heterocyclic compounds
EP2802582A1 (en) *	2012-01-13	2014-11-19	Novartis AG	Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802585A1 (en) *	2012-01-13	2014-11-19	Novartis AG	Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
EP2802581A1 (en) *	2012-01-13	2014-11-19	Novartis AG	7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US8937069B2 (en)	2012-01-13	2015-01-20	Novartis Ag	Substituted pyrrolo[2,3-B]pyrazine compounds and their use
WO2013180183A1 (ja)	2012-05-30	2013-12-05	日本新薬株式会社	芳香族複素環誘導体及び医薬
PT3176170T (pt)	2012-06-13	2019-02-05	Incyte Holdings Corp	Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014087208A2 (en) *	2012-12-06	2014-06-12	Enaltec Labs Pvt. Ltd.	A process of preparing alcaftadine
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
ES2637719T3 (es)	2013-02-13	2017-10-16	Novartis Ag	Compuestos heterocíclicos agonistas del receptor IP
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
CN103364500B (zh) *	2013-06-29	2019-01-22	北京万全德众医药生物技术有限公司	一种用液相色谱法分离测定比拉斯汀原料及其制剂的方法
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MX381180B (es) *	2014-11-18	2025-03-12	Merck Sharp & Dohme	Compuestos aminopirazina con propiedades antagonistas a2a.
CN104447583B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	吡嗪类化合物及其组合物及用途
CN104447584B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104402833B (zh) *	2014-11-20	2016-08-24	广东东阳光药业有限公司	含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) *	2014-12-10	2016-08-24	广东东阳光药业有限公司	吡嗪衍生物及其用途
KR20170115042A (ko) *	2014-12-23	2017-10-16	베르겐바이오 에이에스에이	Akt 키나아제의 저해제
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134320A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
ES2580702B1 (es) *	2015-02-25	2017-06-08	Palobiofarma, S.L.	Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7013213B2 (ja) *	2017-05-26	2022-01-31	日本化薬株式会社	ピラジン化合物
KR20200041315A (ko) *	2017-07-18	2020-04-21	누베이션 바이오 인크.	아데노신 길항제로서의 헤테로시클릭 화합물
SG11202000431PA (en) *	2017-07-18	2020-02-27	Nuvation Bio Inc	1,8-naphthyridinone compounds and uses thereof
CA3097751A1 (en) *	2018-04-20	2019-10-24	Virginia Tech Intellectual Properties, Inc.	Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers
EP3788046A1 (en)	2018-05-04	2021-03-10	Incyte Corporation	Salts of an fgfr inhibitor
IL312465A (en)	2018-05-04	2024-06-01	Incyte Corp	FGFR inhibitor solid forms and processes for their preparation
CN109020881B (zh) *	2018-06-28	2020-04-28	新发药业有限公司	一种阿帕替尼的制备方法
CN112279837B (zh) *	2018-08-17	2022-08-09	迪哲(江苏)医药股份有限公司	吡嗪化合物和其用途
AU2019367187A1 (en) *	2018-10-24	2021-03-25	Leadxpro Ag	Functionalized aminotriazines
EP3904352A4 (en) *	2018-12-28	2022-09-07	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	ARYL SUBSTITUTED COMPOUND, METHOD FOR THE PREPARATION AND USE THEREOF
CN111377906B (zh) *	2018-12-28	2022-09-02	四川科伦博泰生物医药股份有限公司	取代的吡嗪化合物及其制备方法和用途
CN111377873B (zh) *	2018-12-28	2023-03-28	四川科伦博泰生物医药股份有限公司	氨基嘧啶化合物及其制备方法和用途
CN113924095A (zh) *	2019-01-18	2022-01-11	诺维逊生物股份有限公司	作为腺苷拮抗剂的杂环化合物
EP3911324A4 (en)	2019-01-18	2022-08-17	Nuvation Bio Inc.	1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
JP2022517418A (ja) *	2019-01-18	2022-03-08	ニューベイション・バイオ・インコーポレイテッド	アデノシンアンタゴニストとしてのヘテロ環式化合物
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
CN110407677B (zh) *	2019-06-17	2022-10-11	南京先进生物材料与过程装备研究院有限公司	二苯乙二酮类化合物的制备方法及应用
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN112500416B (zh) *	2019-07-30	2021-12-17	厦门宝太生物科技股份有限公司	一种吡唑并三嗪类化合物中间体的制备方法
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
BR112022007163A2 (pt)	2019-10-14	2022-08-23	Incyte Corp	Heterociclos bicíclicos como inibidores de fgfr
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es)	2019-12-04	2022-10-27	Incyte Corp	Derivados de un inhibidor de fgfr
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021146629A1 (en) *	2020-01-17	2021-07-22	Nuvation Bio Inc.	Heterocyclic compounds as adenosine antagonists
WO2021146631A1 (en) *	2020-01-17	2021-07-22	Nuvation Bio Inc.	Heterocyclic compounds as adenosine antagonists
CA3215903A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126101A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
JP2024522189A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN116903634B (zh) *	2023-07-17	2025-07-29	上海美迪西生物医药股份有限公司	一种6-苯基噻吩并[2,3-b]吡嗪的制备方法
WO2025036840A1 (en) *	2023-08-11	2025-02-20	Almirall, S.A.	Pyridine or pyrazine derivatives as collagen vii (c7) inducers and their use in therapy

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9309573D0 (en)	1993-05-10	1993-06-23	Merck Sharp & Dohme	Therapeutic agents
US5686470A (en)	1995-02-10	1997-11-11	Weier; Richard M.	2, 3-substituted pyridines for the treatment of inflammation
EP0888335A4 (en)	1996-03-13	2002-01-02	Smithkline Beecham Corp	NEW PYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CYTOKININ MEDIATOR DISEASES
DE19632549A1 (de) *	1996-08-13	1998-02-19	Merck Patent Gmbh	Arylalkanoylpyridazine
TW520362B (en)	1996-12-05	2003-02-11	Amgen Inc	Substituted pyrimidine compounds and pharmaceutical composition comprising same
CA2315827C (en)	1997-12-19	2007-08-21	Amgen Inc.	Substituted pyridine and pyridazine compounds and their pharmaceutical use
DE69919707T2 (de)	1998-06-19	2005-09-01	Chiron Corp., Emeryville	Glycogen synthase kinase 3 inhibitoren
US6545002B1 (en)	1999-06-01	2003-04-08	University Of Virginia Patent Foundation	Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
JP4324338B2 (ja)	1999-07-02	2009-09-02	エーザイ・アール・アンド・ディー・マネジメント株式会社	縮合イミダゾール化合物及び糖尿病治療薬
NZ517546A (en)	1999-08-31	2003-10-31	Univ Vanderbilt	Selective antagonists of A2B adenosine receptors
US6894021B2 (en)	2000-02-17	2005-05-17	Cv Therapeutics, Inc.	Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation
ATE293962T1 (de)	2000-02-25	2005-05-15	Hoffmann La Roche	Adenosin-rezeptor modulatoren
HUP0300927A2 (hu)	2000-04-26	2003-07-28	Eisai Co., Ltd.	Új pirimidinszármazékok és ezeket tartalmazó defekációt elősegítő gyógyszerkészítmények
WO2002014282A1 (en)	2000-08-11	2002-02-21	Eisai Co., Ltd.	2-aminopyridine compounds and use thereof as drugs
WO2002020495A2 (en)	2000-09-06	2002-03-14	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
KR20030030005A (ko)	2000-09-15	2003-04-16	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제 억제제로서 유용한 피라졸 화합물
EP1360286A2 (en)	2000-09-19	2003-11-12	Chiron Corporation	Characterization of the gsk-3beta protein and methods of use thereof
GB0028383D0 (en)	2000-11-21	2001-01-03	Novartis Ag	Organic compounds
WO2003002566A1 (en)	2001-06-29	2003-01-09	Cv Therapeutics, Inc.	Purine derivatives as a2b adenosine receptor antagonists
TWI330183B (zh)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
US6977300B2 (en)	2001-11-09	2005-12-20	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
US7125993B2 (en)	2001-11-09	2006-10-24	Cv Therapeutics, Inc.	A2B adenosine receptor antagonists
ATE520694T1 (de)	2001-11-09	2011-09-15	Gilead Palo Alto Inc	A2b-adenosinrezeptorantagonisten
WO2003057689A1 (en)	2002-01-02	2003-07-17	Fujisawa Pharmaceutical Co., Ltd.	Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
NZ528591A (en)	2002-02-01	2006-11-30	King Pharmaceuticals Res & Dev	8-heteroaryl xanthine adenosine A2B receptor antagonists and their pharmaceutical use
WO2003068773A1 (en)	2002-02-12	2003-08-21	Glaxo Group Limited	Pyrazolopyridine derivatives
CA2479744A1 (en)	2002-03-28	2003-10-09	Paul E. Finke	Substituted 2,3-diphenyl pyridines
WO2003105666A2 (en)	2002-06-12	2003-12-24	Biogen, Inc.	Method of treating ischemia reperfusion injury using adenosine receptor antagonists
WO2004022540A2 (en)	2002-09-06	2004-03-18	Fujisawa Pharmaceutical Co., Ltd.	Pyridazinone and pyridone derivatives as adenosine antagonists
BR0315053A (pt)	2002-10-03	2005-08-09	Targegen Inc	Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
CA2515197C (en)	2003-02-27	2011-10-18	J. Uriach Y Compania S.A.	Pyrazolopyridine derivates
CN100590125C (zh)	2003-05-06	2010-02-17	Cv医药有限公司	作为a2b腺苷受体拮抗剂的黄嘌呤衍生物
NZ545715A (en)	2003-08-25	2009-02-28	Adenosine Therapeutics Llc	Substituted 8-heteroaryl xanthines
ES2229928B1 (es)	2003-10-02	2006-07-01	Almirall Prodesfarma, S.A.	Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en)	2003-10-03	2003-11-05	Chang Lisa C W	Pyrimidines substituted in the 2,4,6 positions and their different uses
CA2543644A1 (en) *	2003-10-27	2005-05-06	Astellas Pharma Inc.	Pyrazine derivatives and pharmaceutical use thereof
JP4863876B2 (ja)	2003-10-31	2012-01-25	ギリアード・パロ・アルト・インコーポレイテッド	Ａ２ｂアデノシン受容体アンタゴニスト
GB0401336D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
ES2241496B1 (es)	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
ES2274712B1 (es)	2005-10-06	2008-03-01	Laboratorios Almirall S.A.	Nuevos derivados imidazopiridina.
ES2303776B1 (es)	2006-12-29	2009-08-07	Laboratorios Almirall S.A.	Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

2005
- 2005-07-29 ES ES200501876A patent/ES2270715B1/es not_active Expired - Fee Related
2006
- 2006-07-13 UY UY29672A patent/UY29672A1/es unknown
- 2006-07-25 MX MX2008001035A patent/MX2008001035A/es not_active Application Discontinuation
- 2006-07-25 CN CNA2006800340045A patent/CN101268064A/zh active Pending
- 2006-07-25 UA UAA200802498A patent/UA93883C2/ru unknown
- 2006-07-25 NZ NZ565150A patent/NZ565150A/en unknown
- 2006-07-25 KR KR1020087002157A patent/KR20080040681A/ko not_active Withdrawn
- 2006-07-25 SG SG201004274-5A patent/SG162805A1/en unknown
- 2006-07-25 AU AU2006278875A patent/AU2006278875A1/en not_active Abandoned
- 2006-07-25 RU RU2008107264/04A patent/RU2417994C2/ru not_active IP Right Cessation
- 2006-07-25 CA CA002616428A patent/CA2616428A1/en not_active Abandoned
- 2006-07-25 US US11/997,048 patent/US7790728B2/en not_active Expired - Fee Related
- 2006-07-25 EP EP06762807A patent/EP1922313A1/en not_active Withdrawn
- 2006-07-25 JP JP2008523220A patent/JP2009502837A/ja active Pending
- 2006-07-25 WO PCT/EP2006/007318 patent/WO2007017096A1/en not_active Ceased
- 2006-07-25 PE PE2006000899A patent/PE20070407A1/es not_active Application Discontinuation
- 2006-07-28 TW TW095127615A patent/TW200728299A/zh unknown
- 2006-07-28 AR ARP060103279A patent/AR056008A1/es not_active Application Discontinuation
2008
- 2008-01-10 IL IL188725A patent/IL188725A0/en unknown
- 2008-01-11 ZA ZA200800353A patent/ZA200800353B/xx unknown
- 2008-01-17 EC EC2008008113A patent/ECSP088113A/es unknown
- 2008-01-24 NO NO20080451A patent/NO20080451L/no not_active Application Discontinuation
2010
- 2010-06-04 US US12/794,059 patent/US20100273757A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20080040681A (ko)	2008-05-08
RU2008107264A (ru)	2009-09-10
US20090042891A1 (en)	2009-02-12
CN101268064A (zh)	2008-09-17
UA93883C2 (ru)	2011-03-25
ECSP088113A (es)	2008-02-20
MX2008001035A (es)	2008-03-14
WO2007017096A1 (en)	2007-02-15
ZA200800353B (en)	2008-12-31
PE20070407A1 (es)	2007-05-12
US7790728B2 (en)	2010-09-07
ES2270715A1 (es)	2007-04-01
CA2616428A1 (en)	2007-02-15
IL188725A0 (en)	2008-08-07
AR056008A1 (es)	2007-09-12
AU2006278875A1 (en)	2007-02-15
US20100273757A1 (en)	2010-10-28
ES2270715B1 (es)	2008-04-01
NZ565150A (en)	2011-02-25
EP1922313A1 (en)	2008-05-21
SG162805A1 (en)	2010-07-29
RU2417994C2 (ru)	2011-05-10
JP2009502837A (ja)	2009-01-29
UY29672A1 (es)	2007-01-31
NO20080451L (no)	2008-02-11

Publication	Publication Date	Title
TW200728299A (en)	2007-08-01	New pyrazine derivatives
KR102488479B1 (ko)	2023-01-12	인플루엔자 바이러스 감염에 사용하기 위한 인돌
US8470835B2 (en)	2013-06-25	Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
CN101801362B (zh)	2014-01-22	用于治疗病症的方法和组合物
US8389546B2 (en)	2013-03-05	Compounds for modulating TRPV3 function
RS60312B1 (sr)	2020-07-31	Jedinjenja indol karboksamida korisna kao inhibitori kinaze
HUE032847T2 (hu)	2017-11-28	Vegyületek és készítmények mint protein kináz inhibitorok
WO2007022380A3 (en)	2007-06-21	Bis-aryl amide compounds and methods of use
MY147442A (en)	2012-12-14	Imidazoquinolines as lipid kinase inhibitors
WO2008002244A8 (en)	2008-10-09	Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
CN102471329A (zh)	2012-05-23	用作治疗肿瘤性或自身免疫性疾病的前药的呋咱并苯并咪唑
JP6463680B2 (ja)	2019-02-06	脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類
WO2008002245A8 (en)	2008-10-09	Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (gsk3)
UA92181C2 (ru)	2010-10-11	Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
TW200927129A (en)	2009-07-01	Organic compounds
NO20091254L (no)	2009-03-26	Terapeutiske sammensetninger
CN101460507A (zh)	2009-06-17	噻唑基-二氢-吲唑
CY1112255T1 (el)	2015-12-09	Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
WO2008039139A8 (en)	2009-03-19	Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
CN101684098A (zh)	2010-03-31	一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
JP2023533616A (ja)	2023-08-03	Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法
Wurz et al.	2010	Part 2: Structure–activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38α mitogen-activated protein kinase
US10800785B2 (en)	2020-10-13	Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors
US9505756B2 (en)	2016-11-29	Compounds useful for treating disorders related to TRPA1
CN117355507A (zh)	2024-01-05	用作lrrk2激酶抑制剂的嘧啶衍生物